Related Experiment Video
Updated: Jul 15, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Molecular basis of antithrombin deficiency in four Japanese patients with antithrombin gene abnormalities including
Mayu Kyotani1, Kaoru Okumura, Akira Takagi
1Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Insights
Four distinct antithrombin (AT) gene mutations were identified in Japanese patients with AT deficiency. Different mutations impact AT secretion, heparin binding, and cofactor activity, leading to distinct deficiency types.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Antithrombin (AT) deficiency is a genetic disorder predisposing individuals to thrombosis.
- Understanding the molecular basis of AT deficiency is crucial for risk assessment and management.
Observation:
- Four distinct heterozygous mutations in the AT gene were identified in four unrelated Japanese patients.
- Two novel mutations (2417delT [FS-3Stop] and C2640T [Ala59Val]) and two previously reported mutations (T5342C [Ser116Pro] and T72C [Met-32Thr]) were found.
Findings:
- In vitro expression revealed that FS-3Stop-AT and Met-32Thr-AT were not secreted, while Ser116Pro-AT and Ala59Val-AT were secreted normally.
- Ser116Pro mutation impaired heparin binding and reduced cofactor activity.
- Ala59Val mutation showed normal heparin binding but severely reduced cofactor activity.
Implications:
- FS-3Stop and Met-32Thr mutations are associated with Type I AT deficiency (impaired secretion).
- Ser116Pro and Ala59Val mutations are associated with Type II AT deficiency (impaired function).
- These findings highlight diverse molecular mechanisms underlying AT deficiency due to specific AT gene abnormalities.
Abstract:
We analyzed the antithrombin (AT) gene in four unrelated Japanese patients with an AT deficiency, and individually identified four distinct mutations in the heterozygous state. There were two novel mutations, 2417delT leading to a frameshift with a premature termination at amino acid -3 (FS-3Stop) and C2640T resulting in a missense mutation (Ala59Val). Previously reported mutations, T5342C (Ser116Pro) and T72C (Met-32Thr), were also found in the other two patients. To understand the molecular basis responsible for the AT deficiency in these patients, in vitro expression experiments were performed using HEK293 cells transfected with either wild type or respective mutant AT expression vector. We found that -3Stop-AT and -32Thr-AT were not secreted into the culture media, whereas 116Pro-AT and 59Val-AT were secreted normally. We further studied the heparin cofactor activity and the binding to heparin of each recombinant AT molecule. Ser116Pro mutation significantly impaired the binding affinity to heparin resulting in a reduced heparin cofactor activity. In contrast, we found that Ala59Val mutant AT unexpectedly showed a normal affinity to heparin, but severely impaired the heparin cofactor activity. Our findings suggested that FS-3Stop and Met-32Thr mutations are responsible for type I AT deficiency, whereas Ser116Pro and Ala59Val mutations contribute to type II AT deficiency, confirming that there were diverse molecular mechanisms of AT deficiency depend upon discrete AT gene abnormalities as reported previously.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Principles of Pharmacogenetics: Types of Genetic Variants

